Please login to the form below

Not currently logged in
Email:
Password:

antisense drugs

This page shows the latest antisense drugs news and features for those working in and with pharma, biotech and healthcare.

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

The company specialises in antisense drugs, which ‘silence’ RNA and target diseases much closer to their genetic origins than conventional therapies. ... He added: "This is our second antisense drug to demonstrate a strong safety profile and

Latest news

  • AZ makes gene therapy move with 4DMT alliance AZ makes gene therapy move with 4DMT alliance

    have focused on RNA and oligonucleotide-based drugs to switch off the activity of problem genes and gene-editing using CRISPR technology, rather than vector-based gene transfer. ... also working with Ionis on antisense drugs for a range of targets

  • Despite FDA concerns, Akcea rare disease drug clears FDA panel Despite FDA concerns, Akcea rare disease drug clears FDA panel

    There are no approved treatments and drugs such as fibrates or niacin that can usually help control high triglycerides are ineffective, so the only management available is a strict, lifelong diet ... Thrombocytopenia is a recognised side effects with

  • AZ adds another Ionis drug in $330m kidney disease deal AZ adds another Ionis drug in $330m kidney disease deal

    AZ has the option to license additional antisense drugs upon development candidate nomination, it says. ... After many years at the forefront of efforts to develop antisense drugs, Ionis’ pipeline has started to deliver with Biogen-partnered Spinraza

  • Safety issues dampen enthusiasm for Akcea's volanesorsen Safety issues dampen enthusiasm for Akcea's volanesorsen

    There was also a reduction in pancreatitis and abdominal pain with the drug, according to Akcea, which is a wholly owned subsidiary of antisense specialist Ionis Pharmaceuticals. ... programme. That led to speculation that platelet effects could be a

  • Pfizer signs $900m-plus deal with WAVE for metabolic R&D Pfizer signs $900m-plus deal with WAVE for metabolic R&D

    WAVE focuses on the development of antisense and RNA interference (RNAi) drugs that switch off the production of proteins, with an emphasis on tackling the underlying mechanisms of disease. ... This approach will be combined with a liver-targeting

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    510. Isis. Antisense drugs for CVS metabolic and renaldisease. 65. Mirati Therapeutics. ... Exclusive licence. 90. Isis. AZ. Addition to Dec 2012 collaboration to develop antisense drugs in oncology.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Strategic collaboration. 1, 000. Isis/ Janssen. Antisense drugs to treat autoimmune disorders of the GI tract - local and oral therapies (3 programmes).

  • Pharma deals during January 2015 Pharma deals during January 2015

    A $35m payment went in an upfront to Isis as part of its $835m headline deal for a collaboration to discover and develop antisense drugs in autoimmune disorders in the GI ... tract. The deal includes options to license drugs arising from the various

  • Pharma deals during December 2012 Pharma deals during December 2012

    an upfront of $30m, to discover and co-develop antisense drugs to treat three neurological or neuromuscular disorders. In January 2012, Biogen Idec paid Isis an upfront of $29m for an ... 231. Isis / Biogen. Co-development and option to licence.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics